Anabolic-Androgenic Steroids (sold as SARMs)

DMZ, Mebolazine, Dimethazine, D-Zine, mebolazine, di(methasterone) azine, 2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one azine

Dymethazine (DMZ, mebolazine/dimethazine) is an oral anabolic-androgenic STEROID (AAS) — not a SARM and not a peptide, despite being marketed and grouped under "SARM"/"prohormone" branding to imply a mild profile. Chemically it is an azine dimer of two methasterone (methyldrostanolone) units — each a 17alpha-methylated DHT derivative — joined by a nitrogen-nitrogen (azine) bridge at the A-ring 3-position, and in the body it splits into two molecules of methasterone (the same drug sold as "Superdrol"). Because the dimer and its metabolites are all 17alpha-alkylated, it carries classic 17alpha-alkylated hepatotoxicity, including documented cholestatic jaundice — the opposite of "mild." It is an unapproved designer steroid and has never been an approved medicine; its active metabolite methasterone is a US Schedule III controlled anabolic steroid (2012), the Designer Anabolic Steroid Control Act of 2014 broadened Schedule III to capture designer AAS, and it is prohibited in sport by WADA as an exogenous anabolic androgenic steroid (S1.1).

Methylepitiostanol, Havoc, E-Stane, Epi, 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol, 17α-methylepithiostanol, Methyl-epitiostanol, 2,3-thioepoxy madol

Epistane is an anabolic-androgenic STEROID (AAS) — it is NOT a SARM and NOT a peptide, despite being marketed as a "dry SARM" or "prohormone." Chemically it is methylepitiostanol (2α,3α-epithio-17α-methyl-5α-androstan-17β-ol), a 17α-alkylated (oral) derivative of dihydrotestosterone (DHT) carrying a 2,3-epithio group that also confers anti-estrogenic / aromatase-inhibitory activity — the basis for its "dry"/"non-estrogenic" marketing. It was never approved for medical use in any jurisdiction. The 17α-alkyl group makes it orally active but also HEPATOTOXIC — multiple published human case reports document severe, prolonged cholestatic drug-induced liver injury (DILI) with profound jaundice in young men who used epistane (Petrov et al., Arch Toxicol 2020). Like all oral 17α-alkylated AAS it also suppresses the HPTA (endogenous testosterone), adversely alters lipids/cardiovascular risk, and causes androgenic/virilizing effects. It is a designer anabolic steroid — the opposite of "mild" — sold under SARM/prohormone branding, and it is a known undeclared adulterant in "SARM"/supplement products. WADA-prohibited as an exogenous AAS (S1.1a); a US Schedule III controlled anabolic steroid explicitly named under the Designer Anabolic Steroid Control Act of 2014. Not an approved medicine — a controlled designer anabolic steroid; educational information only, not medical, dosing, or legal advice.

Superdrol, M-Drol, Methyldrol, Methyldrostanolone, 17a-methyldrostanolone, 2a,17a-dimethyl-5a-DHT, Methasteron

Methasterone ("Superdrol") is an anabolic-androgenic STEROID — a 17α-alkylated oral steroid derived from DHT — that is NOT a SARM and NOT a peptide. It was never approved as a medicine; it emerged as a "designer steroid" sold as a bodybuilding supplement and is frequently marketed as or alongside "SARMs" and "prohormones" to imply a mild profile. It is a documented cause of severe cholestatic drug-induced liver injury and is a Schedule III controlled anabolic steroid in the US — not approved, controlled designer steroid.

M-Sten, Methyl-Sten, Ultradrol, Methyl-Stenbolone, 2,17α-Dimethyl-δ1-DHT, 2,17α-dimethyl-5α-androsta-1-en-17β-ol-3-one

Methylstenbolone (M-Sten, Ultradrol) is an anabolic-androgenic steroid (AAS) — a 17α-methylated (C17-alkylated) oral derivative of dihydrotestosterone (DHT). It is not a SARM and not a peptide, despite being marketed alongside "SARM" and "prohormone" products to imply a mild profile; it is a full designer anabolic steroid. The headline harm is hepatotoxicity — the 17α-alkyl group drives documented drug-induced liver injury, including a published case of severe cholestatic jaundice (peak bilirubin ~46 mg/dL) after a label-recommended dose of a "supplement" containing it. It also suppresses natural testosterone (HPTA), harms lipids/cardiovascular markers, and can cause virilization. It was never developed or approved as a medicine and is a Schedule III controlled anabolic steroid in the US under the Designer Anabolic Steroid Control Act of 2014.